Pfeiffer E F, Thum C, Raptis S, Beischer W, Ziegler R
Horm Metab Res. 1976;Suppl 6:112-26.
Hypoglycemia in diabetes can be divided into 1) spontaneous hypoglycemic reactions due to absolute or relative overproduction of endogenous insulin or some other blood glucose-lowering substance, as in islet cell adenoma or carcinoma, latent or protodiabetic conditions, (extrapancreatic) tumors and pituitary and/or adrenal disorders; and 2) hypoglycemia caused by exogenous, i.e. therapeutic, measures. The problem of hypoglycemia in insulin-treated diabetics is far from being solved. As revealed by continuous blood glucose monitoring, nocturnal hypoglycemic attacks frequently escape attention especially in juvenile diabetics. Circadian variations in peripheral glucose utilization, rather than changes in plasma insulin activity, are likely to be involved in this mechanism. At least, this was the conclusion drawn from studies carried out by means of a glucose-controlled insulin and glucose infusion system (GCIGIS) -or artificial pancreas-which delivers short-acting insulin and glucose on demand intravenously. Hypoglycemic reactions in patients being treated with oral anti-diabetic agents, on the other hand, should be regarded primarily as one of the side reactions intrinsic to the mechanism of action of some of these drugs, e.g. sulfonylureas, which act mainly via stimulation of secretion of endogenous insulin reserves not responding properly to postprandial blood glucose increments. In the case of glibenclamide, at least partial resensitization of the defective glucose receptor of the beta-cell also becomes operative. A higher incidence of a characteristic type of hypoglycemic reaction was observed soon after glibenclamide therapy was introduced. Better understanding of the drug and dissemination of the information about it to doctors and patients has reduced the number of hypoglycemic reactions caused by glibenclamide to the same proportions as for other sulfonylureas. Hypoglyoemia following therapeutic hypophysectomy retains its position as one of the main hazards of this heroic therapy.
1)内源性胰岛素或其他降血糖物质绝对或相对过量产生导致的自发性低血糖反应,如胰岛细胞瘤或癌、潜在或糖尿病前期状态、(胰腺外)肿瘤以及垂体和/或肾上腺疾病;2)外源性即治疗措施引起的低血糖。胰岛素治疗的糖尿病患者的低血糖问题远未得到解决。连续血糖监测显示,夜间低血糖发作常常被忽视,尤其是在青少年糖尿病患者中。外周葡萄糖利用的昼夜变化,而非血浆胰岛素活性的变化,可能参与了这一机制。至少,这是通过葡萄糖控制的胰岛素和葡萄糖输注系统(GCIGIS)或人工胰腺进行的研究所得出的结论,该系统可根据需要静脉输注短效胰岛素和葡萄糖。另一方面,接受口服抗糖尿病药物治疗的患者发生的低血糖反应,应主要视为这些药物作用机制固有的副作用之一,例如磺脲类药物,其主要通过刺激内源性胰岛素储备分泌起作用,而这些储备对餐后血糖升高反应不佳。就格列本脲而言,β细胞缺陷的葡萄糖受体至少部分重新敏化也起作用。在引入格列本脲治疗后不久,就观察到一种特征性低血糖反应的发生率较高。对该药物的更好理解以及向医生和患者传播相关信息,已使格列本脲引起的低血糖反应数量降至与其他磺脲类药物相同的比例。治疗性垂体切除术后的低血糖仍然是这种激进治疗的主要风险之一。